Working together to bring your innovation to patients. Using Pfizer global expertise to find cutting-edge development & manufacturing solutions
- Development
Pfizer CentreOne® offers
pharmaceutical development ...
- API's & Intermediates
Regulatory intelligence for more
than 150 countries, supporting ...
- Tech Transfer
Learn about tech transfer in
pharma. Helpful resources and ...
- Large Molecule Biologics
An altogether different CDMO with
over 40 years of experience
- Development
Premier Research — the experts in locating rare patient populations. We help you design and recruit for studies to maximize data quality.
Suchergebnisse
Suchergebnisse:
Monday, February 28, 2022. by Fred Little, Rare Disease Canada Lead, Pfizer Canada. When we hear the term “rare disease”, our first instinct is to think that such diseases are uncommon, which is misleading given that 1 in 12 Canadians are affected by a rare disorder, two-thirds of whom are children.
3. März 2022 · On Rare Diseases Day, New Partnerships and Investments Could Deliver Potential Breakthroughs. March 3, 2022. The diseases may be rare, but their impact is profound. There are over 7,000 known rare diseases that affect approximately 400 million people worldwide.
With more than three decades of experience in rare diseases, our broad portfolio aims to address unmet medical needs across four main therapeutic areas: rare hematology, rare endocrine/metabolic, rare cardiology, and rare neurology. Rare Disease Research. Pipeline & Clinical Trials.
Rare Disease. Smaller populations but big impact; Internal Medicine. Extending lifespans worldwide; Inflammation & Immunology. Treatment at the molecular level; Vaccines. Preventing the spread of infections; Oncology. The science of optimism; Anti Infectives. Combatting an evolving risk; Areas of Innovation. Gene Therapy. Breakthroughs become ...
Susanne Riedel Lead Therapeutic Area Rare Diseases. Einige Gentherapien sind hierzulande schon verfügbar, weitere werden in den kommenden Jahren folgen. Die europäische Zulassungsbehörde (EMA) rechnet ab dem Jahr 2025 mit 10-20 neuen Gentherapien pro Jahr. Pfizer prüft in klinischen Studien derzeit das Prinzip einer vektorbasierten ...
2024. RARE DISEASE GRANTS AND CONTRIBUTIONS. Advancing Knowledge and Public Health. Pfizer Rare Disease is built on innovation. We pride ourselves in stretching the limits of traditional partnership and collaborative research models by working in new and meaningful ways with innovators in government, academia, advocacy, and across the industry.
28. Feb. 2022 · 28.02.2022. Setzen Sie ein Zeichen. 50.000 Stimmen für eine solide Finanzierung der Zentren für Seltene Erkrankungen. In Deutschland leben ca. 4 Millionen Menschen mit einer seltenen Erkrankung. Etwa 70 % der Betroffenen leiden bereits im Kindes- oder Jugendalter an den Symptomen. Wir möchten das Leben dieser Menschen und ihrer Familien verbessern.
